Enhancement of HPV therapeutic peptide-based vaccine efficacy through combination therapies and improved delivery strategies: A review
Human papillomavirus (HPV) has been linked to the development of various cancers, including head and neck, cervical, vaginal, penile, and anal cancers. The development of therapeutic vaccines against HPV-positive tumors is crucial for protecting individuals already infected with HPV, preventing tumo...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2396710 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849687412432699392 |
|---|---|
| author | Rongyu Liu Xinlin He Wanying Bao Zhengyu Li |
| author_facet | Rongyu Liu Xinlin He Wanying Bao Zhengyu Li |
| author_sort | Rongyu Liu |
| collection | DOAJ |
| description | Human papillomavirus (HPV) has been linked to the development of various cancers, including head and neck, cervical, vaginal, penile, and anal cancers. The development of therapeutic vaccines against HPV-positive tumors is crucial for protecting individuals already infected with HPV, preventing tumor progression, and effectively treating the disease. The HPV therapeutic peptide-based vaccines demonstrate specificity and safety advantages by targeting specific epitopes while minimizing the risk of allergic or autoimmune reactions. However, HPV therapeutic peptide-based vaccines typically lack immunogenicity and frequently fail to induce effective immune responses. Therefore, there is a need for more effective approaches to improve the immunogenicity of HPV peptide-based vaccines. Here, we review relevant research and possible uses for increasing the immunogenicity and therapeutic efficacy of HPV peptide-based vaccines through combined therapy and improved delivery strategies. Additional research is necessary to validate the application of combination therapy and delivery strategy modifications as standard treatment approaches for HPV therapeutic peptide-based vaccines. |
| format | Article |
| id | doaj-art-e771eb2fbbd24cf98e53da1a3bc43c22 |
| institution | DOAJ |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-e771eb2fbbd24cf98e53da1a3bc43c222025-08-20T03:22:19ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2396710Enhancement of HPV therapeutic peptide-based vaccine efficacy through combination therapies and improved delivery strategies: A reviewRongyu Liu0Xinlin He1Wanying Bao2Zhengyu Li3Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, People’s Republic of ChinaDepartment of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, People’s Republic of ChinaDepartment of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, People’s Republic of ChinaDepartment of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, People’s Republic of ChinaHuman papillomavirus (HPV) has been linked to the development of various cancers, including head and neck, cervical, vaginal, penile, and anal cancers. The development of therapeutic vaccines against HPV-positive tumors is crucial for protecting individuals already infected with HPV, preventing tumor progression, and effectively treating the disease. The HPV therapeutic peptide-based vaccines demonstrate specificity and safety advantages by targeting specific epitopes while minimizing the risk of allergic or autoimmune reactions. However, HPV therapeutic peptide-based vaccines typically lack immunogenicity and frequently fail to induce effective immune responses. Therefore, there is a need for more effective approaches to improve the immunogenicity of HPV peptide-based vaccines. Here, we review relevant research and possible uses for increasing the immunogenicity and therapeutic efficacy of HPV peptide-based vaccines through combined therapy and improved delivery strategies. Additional research is necessary to validate the application of combination therapy and delivery strategy modifications as standard treatment approaches for HPV therapeutic peptide-based vaccines.https://www.tandfonline.com/doi/10.1080/21645515.2024.2396710Human papillomaviruspeptide-based vaccinescombination therapytumorimmunogenicity |
| spellingShingle | Rongyu Liu Xinlin He Wanying Bao Zhengyu Li Enhancement of HPV therapeutic peptide-based vaccine efficacy through combination therapies and improved delivery strategies: A review Human Vaccines & Immunotherapeutics Human papillomavirus peptide-based vaccines combination therapy tumor immunogenicity |
| title | Enhancement of HPV therapeutic peptide-based vaccine efficacy through combination therapies and improved delivery strategies: A review |
| title_full | Enhancement of HPV therapeutic peptide-based vaccine efficacy through combination therapies and improved delivery strategies: A review |
| title_fullStr | Enhancement of HPV therapeutic peptide-based vaccine efficacy through combination therapies and improved delivery strategies: A review |
| title_full_unstemmed | Enhancement of HPV therapeutic peptide-based vaccine efficacy through combination therapies and improved delivery strategies: A review |
| title_short | Enhancement of HPV therapeutic peptide-based vaccine efficacy through combination therapies and improved delivery strategies: A review |
| title_sort | enhancement of hpv therapeutic peptide based vaccine efficacy through combination therapies and improved delivery strategies a review |
| topic | Human papillomavirus peptide-based vaccines combination therapy tumor immunogenicity |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2396710 |
| work_keys_str_mv | AT rongyuliu enhancementofhpvtherapeuticpeptidebasedvaccineefficacythroughcombinationtherapiesandimproveddeliverystrategiesareview AT xinlinhe enhancementofhpvtherapeuticpeptidebasedvaccineefficacythroughcombinationtherapiesandimproveddeliverystrategiesareview AT wanyingbao enhancementofhpvtherapeuticpeptidebasedvaccineefficacythroughcombinationtherapiesandimproveddeliverystrategiesareview AT zhengyuli enhancementofhpvtherapeuticpeptidebasedvaccineefficacythroughcombinationtherapiesandimproveddeliverystrategiesareview |